Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Discussing MRD testing with patients

William Wierda • 10 Sep 2020
SOHO 2020
Chronic Lymphocytic Leukemia Leukemia

William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the use of commercialized minimal residual disease (MRD) measurements and what this means for patients specifcally. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from William Wierda

1:12
Primary analysis of TRANSCEND-CLL-004: liso-cel in R/R CLL
William Wierda • 10 Jun 2023
2:08
Disease characteristics impacting treatment decisions in CLL
William Wierda • 10 Jun 2023
2:20
Genomic evolution and resistance to pirtobrutinib in CLL: insights from the BRUIN study
William Wierda • 10 Jun 2023
1:07
The current status of liso-cel in CLL and updates from the TRANSCEND-CLL-004 trial
William Wierda • 28 Sep 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals